Corbenic Partners’s AbbVie ABBV Stock Holding History

Corbenic Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$6K	Hold	37	–	–	﹤0.01%	145
2022 Q1	$6K	Hold	37	–	–	﹤0.01%	169
2021 Q4	$5K	Sell	37 -155	-81%	-$18.3K	﹤0.01%	205
2021 Q3	$21K	Buy	192 +1	+0.5%	+$114	0.01%	116
2021 Q2	$21K	Buy	191 +1	+0.5%	+$113	0.01%	123
2021 Q1	$21K	Buy	190 +104	+121%	+$11.1K	0.01%	121
2020 Q4	$9K	Hold	86	–	–	﹤0.01%	130
2020 Q3	$8K	Hold	86	–	–	﹤0.01%	113
2020 Q2	$8K	Buy	+86	New	+$7.57K	﹤0.01%	106
2017 Q4	$15K	Hold	160	–	–	0.02%	113
2017 Q3	$14K	Buy	+160	New	+$12.2K	0.02%	121
2017 Q1	–	Sell	-153	Closed	-$10K	–	199
2016 Q4	$10K	Hold	153	–	–	0.01%	133
2016 Q3	$10K	Buy	153 +28	+22%	+$1.81K	0.01%	126
2016 Q2	$8K	Buy	+125	New	+$7.62K	0.01%	133

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corbenic Partners's ABBV Position: Q2 2022 in Review

Corbenic Partners held its AbbVie (ABBV) position steady in Q2 2022 at 37 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #145.

Corbenic Partners first reported a position in ABBV in Q2 2016 and has held it in 14 quarters since. The position peaked at $21K in Q3 2021. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Corbenic Partners held 37 shares of AbbVie worth $6K as of Q2 2022.
Corbenic Partners left its AbbVie share count unchanged in Q2 2022.
AbbVie made up ﹤0.01% of Corbenic Partners's portfolio in Q2 2022, its #145 holding.
Corbenic Partners first reported a position in AbbVie in Q2 2016 and has held it in 14 quarters since.
Corbenic Partners's AbbVie position peaked at $21K in Q3 2021.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.